These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 25448108)

  • 1. Effect of cationic liposomes on BCG trafficking and vaccine-induced immune responses following a subcutaneous immunization in mice.
    Derrick SC; Yang A; Parra M; Kolibab K; Morris SL
    Vaccine; 2015 Jan; 33(1):126-32. PubMed ID: 25448108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of Unconventional T Cells by a Mutant Mycobacterium bovis BCG Strain Formulated in Cationic Liposomes Correlates with Protection against Mycobacterium tuberculosis Infections of Immunocompromised Mice.
    Derrick SC; Yabe I; Morris S; Cowley S
    Clin Vaccine Immunol; 2016 Jul; 23(7):638-47. PubMed ID: 27226281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerating the secondary immune response by inactivating CD4(+)CD25(+) T regulatory cells prior to BCG vaccination does not enhance protection against tuberculosis.
    Quinn KM; Rich FJ; Goldsack LM; de Lisle GW; Buddle BM; Delahunt B; Kirman JR
    Eur J Immunol; 2008 Mar; 38(3):695-705. PubMed ID: 18266274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis.
    Waeckerle-Men Y; Bruffaerts N; Liang Y; Jurion F; Sander P; Kündig TM; Huygen K; Johansen P
    Vaccine; 2013 Feb; 31(7):1057-64. PubMed ID: 23273509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced immunogenicity of BCG vaccine by using a viral-based GM-CSF transgene adjuvant formulation.
    Wang J; Zganiacz A; Xing Z
    Vaccine; 2002 Jul; 20(23-24):2887-98. PubMed ID: 12126899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prime-boost vaccination strategy with bacillus Calmette-Guérin (BCG) and liposomized alpha-crystalline protein 1 reinvigorates BCG potency.
    Siddiqui KF; Amir M; Khan N; Rama Krishna G; Sheikh JA; Rajagopal K; Agrewala JN
    Clin Exp Immunol; 2015 Aug; 181(2):286-96. PubMed ID: 25845290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal administration of Mycobacterium bovis BCG induces superior protection against aerosol infection with Mycobacterium tuberculosis in mice.
    Derrick SC; Kolibab K; Yang A; Morris SL
    Clin Vaccine Immunol; 2014 Oct; 21(10):1443-51. PubMed ID: 25143340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis.
    Aldwell FE; Cross ML; Fitzpatrick CE; Lambeth MR; de Lisle GW; Buddle BM
    Vaccine; 2006 Mar; 24(12):2071-8. PubMed ID: 16332403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
    Goonetilleke NP; McShane H; Hannan CM; Anderson RJ; Brookes RH; Hill AV
    J Immunol; 2003 Aug; 171(3):1602-9. PubMed ID: 12874255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photochemically-Mediated Inflammation and Cross-Presentation of
    Waeckerle-Men Y; Kotkowska ZK; Bono G; Duda A; Kolm I; Varypataki EM; Amstutz B; Meuli M; Høgset A; Kündig TM; Halin C; Sander P; Johansen P
    Front Immunol; 2022; 13():815609. PubMed ID: 35173729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation of a mmaA4 gene deletion mutant of Mycobacterium bovis BCG in cationic liposomes significantly enhances protection against tuberculosis.
    Derrick SC; Dao D; Yang A; Kolibab K; Jacobs WR; Morris SL
    PLoS One; 2012; 7(3):e32959. PubMed ID: 22442674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with Single Oral Dose of Alginate-Encapsulated BCG Elicits Effective and Long-Lasting Mucosal Immune Responses.
    Hosseini M; Dobakhti F; Pakzad SR; Ajdary S
    Scand J Immunol; 2015 Dec; 82(6):489-97. PubMed ID: 26286252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
    Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
    Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against an aerogenic Mycobacterium tuberculosis infection in BCG-immunized and DNA-vaccinated mice is associated with early type I cytokine responses.
    Goter-Robinson C; Derrick SC; Yang AL; Jeon BY; Morris SL
    Vaccine; 2006 Apr; 24(17):3522-9. PubMed ID: 16519971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy.
    Lu M; Xia ZY; Bao L
    Cell Immunol; 2013; 285(1-2):111-7. PubMed ID: 24177251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of remaining live BCG organisms in vaccinated mice on the maintenance of immunity to tuberculosis.
    Olsen AW; Brandt L; Agger EM; van Pinxteren LA; Andersen P
    Scand J Immunol; 2004 Sep; 60(3):273-7. PubMed ID: 15320884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated induction of mycobacterial antigen-specific CD8+ T cells in the Mycobacterium tuberculosis-infected lung by subcutaneous vaccination with Mycobacterium bovis bacille Calmette-Guérin.
    Begum D; Umemura M; Yahagi A; Okamoto Y; Hamada S; Oshiro K; Matsuzaki G
    Immunology; 2009 Dec; 128(4):556-63. PubMed ID: 19930045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of different formulations of oral Mycobacterium bovis Bacille Calmette-Guérin (BCG) vaccine in rodent models for immunogenicity and protection against aerosol challenge with M. bovis.
    Clark S; Cross ML; Smith A; Court P; Vipond J; Nadian A; Hewinson RG; Batchelor HK; Perrie Y; Williams A; Aldwell FE; Chambers MA
    Vaccine; 2008 Oct; 26(46):5791-7. PubMed ID: 18789366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.
    Badell E; Nicolle F; Clark S; Majlessi L; Boudou F; Martino A; Castello-Branco L; Leclerc C; Lewis DJ; Marsh PD; Gicquel B; Winter N
    Vaccine; 2009 Jan; 27(1):28-37. PubMed ID: 18977269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary immune responses during primary mycobacterium bovis- Calmette-Guerin bacillus infection in C57Bl/6 mice.
    Fulton SA; Martin TD; Redline RW; Henry Boom W
    Am J Respir Cell Mol Biol; 2000 Mar; 22(3):333-43. PubMed ID: 10696070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.